Lee Hung

Lee Hung asked about Crinetics' strategy for selecting candidates in the obesity space for 2025 and what criteria its GLP-1 or GIP programs must meet to advance in a highly competitive landscape.

Answer

CEO R. Struthers stated that the company is aiming for a 'best-in-class profile' and will not settle for less than a molecule they believe is near 'perfection.' Key criteria include superior manufacturability and tolerability, leveraging the advantages of small molecules over peptides to achieve an optimal clinical profile.

Inquired about the recent slight slowdown in ZYNTEGLO patient starts, asking if it was due to timing, and questioned the reason for a small decrease in the company's restricted cash balance.

Answer

The dip in ZYNTEGLO starts was attributed to timing, with acceleration expected due to strong demand, scheduled patients, and expanded manufacturing capacity. The decrease in restricted cash was due to a small release following a change in a banking relationship.